Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Intravesical Mitomycin Plus BCG for Non-Muscle Invasive Bladder Cancer
NCT02311101Phase 1Completed
- Sponsor
- UT Health San Antonio
- Start
- Mar 2012
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of mitomycin c in non-muscle-invasive bladder cancer (NMIBC) (4 arms), sponsored by UT Health San Antonio. Primary endpoint: Maximum Tolerated Dose up to 3 months. Started Mar 2012; status: completed.
02
Drugs
mitomycin c
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT02311101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02311101.